Tumorschmerztherapie in Deutschland: Ergebnisse und Analysen einer Befragung von Ärzten

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • R. Sabatowski - , University of Cologne (Author)
  • E. R. Arens - , Johnson & Johnson (Author)
  • I. Waap - , Johnson & Johnson (Author)
  • L. Radbruch - , University of Cologne (Author)

Abstract

The German regulations for opioid prescriptions have been changed in February 1998. The regulations have been made much more easier and should therefore have improved the pain management in Germany. We investigated the knowledge of the WHO analgesic ladder and how they have been followed in a nation-wide survey among physicians not specialised in pain management. Only 9% of the questionnaires were returned. Although the majority of the physicians (93%) reported knowledge about the WHO recommendations for the treatment of cancer pain, more than 15% of the participating physicians rated transdermal fentanyl as a weak opioid or even as a non-opioid. A negative pain management index in 15% of the patients gave evidence of poor quality in pain management. The majority of patients (84%) did not receive immediate release analgesics for the treatment of breakthrough pain. Continuous medical education is still necessary before a further alleviation of regulations will help to reduce the undertreatment of patients suffering from cancer pain in Germany.

Translated title of the contribution
Cancer pain management in Germany - Results and analysis of a questionnaire

Details

Original languageGerman
Pages (from-to)241-247
Number of pages7
JournalSchmerz
Volume15
Issue number4
Publication statusPublished - 2001
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 11810362

Keywords

Sustainable Development Goals

Keywords

  • Cancer pain management, Opioids, Pain management index, WHO-step-ladder